Mesa Laboratories declared a quarterly dividend of $0.16 per share, payable on September 15, 2026.
Quiver AI Summary
Mesa Laboratories, Inc. has announced a quarterly dividend of $0.16 per share, payable on September 15, 2026, to shareholders on record by August 31, 2026. The company, which specializes in life science tools and quality control solutions for the pharmaceutical, healthcare, and medical device sectors, aims to ensure product integrity and enhance patient and worker safety. The press release also includes forward-looking statements that involve risks and uncertainties that could lead to actual results differing from expectations, such as changes in economic conditions and competition. Mesa advises shareholders to refer to its Annual Report for more information about potential risks affecting the company's performance.
Potential Positives
- Mesa Laboratories, Inc. has declared a regular quarterly dividend of $0.16 per share, demonstrating financial stability and a commitment to returning value to shareholders.
- The dividend payout schedule indicates a proactive approach to shareholder engagement, with payments set for September 15, 2026, highlighting the company's confidence in its ongoing operations.
- The company's position as a global leader in life science tools and quality control solutions emphasizes its importance in critical industries, which can support long-term growth and investor interest.
- This press release reinforces Mesa's standing in the market and signals to investors that the company is committed to sustainable practices and profits.
Potential Negatives
- The mention of forward-looking statements highlights potential risks and uncertainties that could negatively impact the company's future performance, which may concern investors.
- The press release does not provide specific information on the company's financial performance or reasons for the dividend declaration, leaving shareholders without clear insights into profitability or growth.
- Addressing profit margin pressure and unknown risks associated with competition could imply challenges ahead, potentially alarming stakeholders about the company's stability.
FAQ
What is the announced quarterly dividend for Mesa Laboratories?
Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock.
When will the dividend be payable to shareholders?
The dividend will be payable on September 15, 2026, to shareholders of record on August 31, 2026.
What industries does Mesa Laboratories serve?
Mesa Laboratories serves the pharmaceutical, healthcare, and medical device industries with life science tools and quality control solutions.
Where can I find more information about Mesa’s financial risks?
Additional information about financial risks can be found in Mesa's Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K.
What should investors know about forward-looking statements?
Forward-looking statements involve risks and uncertainties, and actual results may differ from those anticipated in the press release.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MLAB Insider Trading Activity
$MLAB insiders have traded $MLAB stock on the open market 9 times in the past 6 months. Of those trades, 3 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:
- JOHN SAKYS (CFO) has made 0 purchases and 2 sales selling 4,050 shares for an estimated $376,871.
- BRIAN DAVID ARCHBOLD (SVP Operations) has made 0 purchases and 2 sales selling 3,667 shares for an estimated $341,745.
- SHIRAZ SHABANALI LADIWALA purchased 3,500 shares for an estimated $252,805
- R TONY TRIPENY purchased 1,315 shares for an estimated $99,940
- MARK CHRISTOPHER CAPONE purchased 1,301 shares for an estimated $99,331
- LYNDSEY ELIZABETH CRENNEN (CAO) has made 0 purchases and 2 sales selling 560 shares for an estimated $51,509.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$MLAB Revenue
$MLAB had revenues of $65.1M in Q3 2026. This is an increase of 3.64% from the same period in the prior year.
You can track MLAB financials on Quiver Quantitative's MLAB stock page.
You can access data on MLAB stock through the Quiver Quantitative API.
$MLAB Hedge Fund Activity
We have seen 73 institutional investors add shares of $MLAB stock to their portfolio, and 52 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GENEVA CAPITAL MANAGEMENT LLC removed 178,713 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $15,801,803
- LONG PATH PARTNERS LP added 178,360 shares (+78.5%) to their portfolio in Q1 2026, for an estimated $15,770,591
- AQR CAPITAL MANAGEMENT LLC added 100,424 shares (+143.2%) to their portfolio in Q1 2026, for an estimated $8,879,490
- MASON CAPITAL MANAGEMENT LLC removed 70,300 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,215,926
- MONIMUS CAPITAL MANAGEMENT, LP added 60,450 shares (+148.0%) to their portfolio in Q1 2026, for an estimated $5,344,989
- JANE STREET GROUP, LLC removed 56,371 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,984,323
- BOSTON PARTNERS added 55,335 shares (+25.9%) to their portfolio in Q1 2026, for an estimated $4,892,720
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2026, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
